Search results
Results from the WOW.Com Content Network
Noubar Afeyan (Western Armenian: Նուպար Աֆէեան; born in 1962) is an American-Canadian entrepreneur, inventor, and philanthropist. [1] [2] He is best known for co-founding the biotechnology company Moderna, through his venture capital firm, Flagship Pioneering, and for co-founding humanitarian projects such as Aurora Prize and The Future Armenian.
Before joining Moderna, Bancel was the CEO of French diagnostics company BioMérieux. Bancel is a partner at Flagship Pioneering, and has served on the boards of Indigo Agriculture, Boston's Museum of Science, and Qiagen. As of May 2023, his net worth was estimated at US$4.1 billion, owning about 8% of Moderna. [2]
In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share. [25] [26] The first mRNA vaccine developed by Moderna was for influenza in 2015, and its first antibody encoded by mRNA was in 2019. [6]
Its investors just got some bullish news last week -- news that could unlock a $10 billion market for the company. Let's check out the details. A healthcare worker prepares to vaccinate an individual.
Net worth: $220.8 billion Larry Ellison, the founder and chief technology officer of Oracle, gained $11.7 billion as Oracle shares rallied with the broader tech sector. The stock ended the day 5.5 ...
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...
Moderna reports loss for another quarter as it works to regain ... But there's good news ahead: The company expects to finally break even in 2026. ... the company reported a $3.6 billion net loss ...
In 2014 Rossi retired from his functions at the board and as a scientific advisor at Moderna. [2] In 2015 Rossi was scientific co-founder of Intellia Therapeutics. In 2016 Rossi co-founded Magenta Therapeutics. Rossi was involved in the foundation of Stelexis Therapeutics, which develops new medication for treating cancerous stem cells.